Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis

A. Matsukawa, P. Rajwa, T. Kawada, K. Bekku, E. Laukhtina, J. Klemm, B. Pradere, K. Mori, PI. Karakiewicz, T. Kimura, P. Chlosta, SF. Shariat, T. Yanagisawa

. 2024 ; 29 (6) : 716-725. [pub] 20240406

Jazyk angličtina Země Japonsko

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013709
E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2003-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy

PubMed 38582807
DOI 10.1007/s10147-024-02485-4
Knihovny.cz E-zdroje

BACKGROUND: Triplet therapy, androgen receptor signaling inhibitors (ARSIs) plus docetaxel plus androgen-deprivation therapy (ADT), is a novel guideline-recommended treatment for metastatic hormone-sensitive prostate cancer (mHSPC). However, the optimal selection of the patient most likely to benefit from triplet therapy remains unclear. METHODS: We performed a systematic review, meta-analysis, and network meta-analysis to assess the oncologic benefit of triplet therapy in mHSPC patients stratified by disease volume and compare them with doublet treatment regimens. Three databases and meeting abstracts were queried in March 2023 for randomized controlled trials (RCTs) evaluating patients treated with systemic therapy for mHSPC stratified by disease volume. Primary interests of measure were overall survival (OS). We followed the PRISMA guideline and AMSTAR2 checklist. RESULTS: Overall, eight RCTs were included for meta-analyses and network meta-analyses (NMAs). Triplet therapy outperformed docetaxel plus ADT in terms of OS in both patients with high-(pooled HR: 0.73, 95%CI 0.64-0.84) and low-volume mHSPC (pooled HR: 0.71, 95%CI 0.52-0.97). There was no statistically significant difference between patients with low- vs. high-volume in terms of OS benefit from adding ARSI to docetaxel plus ADT (p = 0.9). Analysis of treatment rankings showed that darolutamide plus docetaxel plus ADT (90%) had the highest likelihood of improved OS in patients with high-volume disease, while enzalutamide plus ADT (84%) had the highest in with low-volume disease. CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013709
003      
CZ-PrNML
005      
20240905133824.0
007      
ta
008      
240725s2024 ja f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10147-024-02485-4 $2 doi
035    __
$a (PubMed)38582807
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/000000023324762X
245    10
$a Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis / $c A. Matsukawa, P. Rajwa, T. Kawada, K. Bekku, E. Laukhtina, J. Klemm, B. Pradere, K. Mori, PI. Karakiewicz, T. Kimura, P. Chlosta, SF. Shariat, T. Yanagisawa
520    9_
$a BACKGROUND: Triplet therapy, androgen receptor signaling inhibitors (ARSIs) plus docetaxel plus androgen-deprivation therapy (ADT), is a novel guideline-recommended treatment for metastatic hormone-sensitive prostate cancer (mHSPC). However, the optimal selection of the patient most likely to benefit from triplet therapy remains unclear. METHODS: We performed a systematic review, meta-analysis, and network meta-analysis to assess the oncologic benefit of triplet therapy in mHSPC patients stratified by disease volume and compare them with doublet treatment regimens. Three databases and meeting abstracts were queried in March 2023 for randomized controlled trials (RCTs) evaluating patients treated with systemic therapy for mHSPC stratified by disease volume. Primary interests of measure were overall survival (OS). We followed the PRISMA guideline and AMSTAR2 checklist. RESULTS: Overall, eight RCTs were included for meta-analyses and network meta-analyses (NMAs). Triplet therapy outperformed docetaxel plus ADT in terms of OS in both patients with high-(pooled HR: 0.73, 95%CI 0.64-0.84) and low-volume mHSPC (pooled HR: 0.71, 95%CI 0.52-0.97). There was no statistically significant difference between patients with low- vs. high-volume in terms of OS benefit from adding ARSI to docetaxel plus ADT (p = 0.9). Analysis of treatment rankings showed that darolutamide plus docetaxel plus ADT (90%) had the highest likelihood of improved OS in patients with high-volume disease, while enzalutamide plus ADT (84%) had the highest in with low-volume disease. CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a antagonisté androgenů $x terapeutické užití $7 D000726
650    _2
$a antagonisté androgenních receptorů $x terapeutické užití $7 D059002
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a docetaxel $x terapeutické užití $x aplikace a dávkování $7 D000077143
650    12
$a síťová metaanalýza $7 D000071076
650    12
$a nádory prostaty $x farmakoterapie $x mortalita $x patologie $7 D011471
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a tumor burden $7 D047368
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Klemm, Jakob $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Chlosta, Piotr $u Department of Urology, Jagiellonian University, Medical College, Krakow, Poland
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at
700    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
773    0_
$w MED00005747 $t International journal of clinical oncology $x 1437-7772 $g Roč. 29, č. 6 (2024), s. 716-725
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38582807 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133818 $b ABA008
999    __
$a ok $b bmc $g 2143482 $s 1225575
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 29 $c 6 $d 716-725 $e 20240406 $i 1437-7772 $m International journal of clinical oncology $n Int J Clin Oncol $x MED00005747
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace